Assessment of liver fibrosis: Can serum become the sample of choice?

Clinical Chemistry

Volumn 51, Issue 10, 2005, Pages 1763-1764

  Dufour, D Robert ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; ASPARTATE AMINOTRANSFERASE; HAPTOGLOBIN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ALCOHOL LIVER DISEASE; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; EDITORIAL; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FIBROSIS; PROGNOSIS; RISK ASSESSMENT;

DECISION SUPPORT SYSTEMS, CLINICAL; DIAGNOSIS, COMPUTER-ASSISTED; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; SENSITIVITY AND SPECIFICITY;

HEPATITIS C VIRUS;

EID: 25444433571     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.056929     Document Type: Editorial

References (20)

1. Lok A, McMahon B. Chronic hepatitis B. Hepatology 2001;34:1225-41.
2. Strader D, Wright T, Thomas D, Seeff L. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
3. Afdhal N, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004;99:1160-4.
4. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48-54.
5. MacDonald A, Burden A. Noninvasive monitoring for methotrexate hepatotoxicity. Br J Dermatol 2005;152:405-8.
6. Oberti F, Valsesia E, Pilette C, Rousselet M, Bedossa P, Aube C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997;113:1609-16.
7. Trinchet J. Clinical use of serum markers of fibrosis in chronic hepatitis. J Hepatol 1995;22:89-95.
8. Forns X, Ampurdanes S, Llovet J, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-92.
9. Wai C, Greenson J, Fontana R, Kalbfleisch J, Marrero J, Conjeevaram H, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26.
10. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-75.
11. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51:1867-73.
12. Blanc J, Bioulac-Sage P, Balabaud C, Desmouliere A. Investigation of liver fibrosis in clinical practice. Hepatol Res 2005;32:1-8.
13. Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004; 50:1344-55.
14. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002;9:128-33.
15. Poynard T, McHutchison J, Manns M, Myers R, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003;38:481-92.
16. Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003;49:450-4.
17. Rosenthal-Allieri M, Peritore M, Tran A, Halfon P, Benzaken S, Bernard A. Analytical variability of the Fibrotest proteins. Clin Biochem 2005;38: 473-8.
18. Myers R, Tainturier M, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003;39:222-30.
19. Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005;3:167-74.
20. Afdhal N. Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis? Clin Chem 2004;50:1299-300.